Raising Questions About ESWT In Heel Pain Article
- Volume 17 - Issue 7 - July 2004
- 5422 reads
- 0 comments
First, I’d like to say that the article on adult-acquired flatfoot (AAF) was insightful and thorough (see the cover story “A New Approach To Adult-Acquired Flatfoot,” pg. 32, May issue). It is now my reference on AAF. However, I found that the heel pain article left questions unanswered (see “Conquering Conservative Care For Heel Pain,” pg. 48, May issue). I wonder why James Losito, DPM, offered his comments on Extracorporeal Shockwave Therapy (ESWT) while having very limited knowledge of ESWT.
Out of the three methods of generating shockwave, Dr. Losito only describes one. By his own admission, he is only familiar with the electrohydraulic method offered by the Ossatron device (Healthtronics). He makes sort of a leap of faith when he suggests that because the Ossatron was the first FDA approved device and is the most powerful, it is better than the other FDA approved device, the newer and more advanced Dornier Epos Ultra.
Further, the cautions he lists are actually contraindications. He also fails to include bleeding disorders, the presence of metal for implants, as well as patients on chemotherapy as additional contraindications, just to name a few.
Dr. Losito also should have mentioned that due to the intense pain produced by the Ossatron’s shockwave being aimed through the plantar aspect of the foot directly into the calcaneus, most patients require IV sedation prior to complete foot and ankle block. All people in the treatment room must also wear hearing protection.
His failure to mention the Dornier Epos Ultra’s precise aiming capabilities (from the inclusion in design of real-time ultrasound imaging), and the fact that the Epos Ultra requires only a simple ankle block, suggests that maybe an unintentional bias exists.
Enough controversy exists about the efficacy of ESWT. This controversy is stretched and expressed mostly by the medical directors of insurance plans who do not want to pay for the procedure. Those of us who have experience with ESWT for plantar fasciitis know that ESWT is now the gold standard for the treatment of chronic plantar fasciitis. It is important to our patients that the podiatry profession does not unnecessarily create controversy over which of the two FDA-approved devices is the most effective. I have seen remarkable results with both devices six months after patients have had the procedure.
I have been certified on the Ossatron for nearly three years and on the Epos Ultra device for two years. I have at my disposal the ability to use either device, but I have found the Epos Ultra easier to use. Additionally, since the Epos Ultra is aimed from medial to lateral through the plantar fascia, and not directly at the calcaneus, there is less immediate post-procedure discomfort for patients.
— Robert S. Steinberg, DPM
Section Chief-Podiatric Surgery,
Department of Surgery
Norwegian American Hospital